Primary pulmonary hypertension in a patient with HIV infection

Acta Cardiologica

Volumn 53, Issue 6, 1998, Pages 367-369

  Conraads, Viviane M ^a   Colebunders, Robert L ^a   Boshoff, Chris ^a   Van Marck, Erik ^b   Bosmans, Johan M ^a   Claeys, Marc J ^a   Vrints, Christiaan J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Endothelium dysfunction; HIV; Primary pulmonary hypertension

Indexed keywords

ANTIVIRUS AGENT; DIGITALIS; DIURETIC AGENT; WARFARIN; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PULMONARY HYPERTENSION; SYNCOPE;

ADULT; CD4 LYMPHOCYTE COUNT; FATAL OUTCOME; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE;

EID: 0032457132     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268-1271.
2. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-2727.
3. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73(1): 37-45.
4. Higenbottam T. Pathophysiology of pulmonary hypertension. A role for endothelial dysfunction. Chest 1994; 105 (S): 7-12.
5. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
6. Christman BW, McPherson CD, Newman J, King GA, Bernard GR, Groves B M, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327: 70-75.
7. Giaid A, Yanagisawa M, Langleben D, Michel RD, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
8. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
9. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-1174.
10. Roberts J, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447-453.
11. Jacques C, Richmond G, Tierny L, Curtis JL, McKerrow J, Warnock ML. Primary pulmonary hypertension and human immunodeficiency virus infection in a non-hemophiliac man. Hum Pathol 1992; 23: 191-194.
12. Meyrick B, Perkett EA, Brigham KL. Inflammation and models of chronic pulmonary hypertension. Am Revue Respir Dis 1987; 136: 765-767.
13. Vogel J, Hinrichs S, Reynolds R, Luciw P, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606-611.
14. Nakamura S, Salahuddin SZ, Biberfeld P, Ensoli B, Parkham PD, Wong-Staal F, Gallo RC. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ cell. Science 1988; 242: 426-429.
15. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-I stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345: 84-86.
16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.